Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Dividend Stocks to Invest in Under $50. On March 2, Argus upgraded ...
NBC Washington

Pfizer, BioNTech Say Trial Data Shows COVID-19 Vaccine More Than 90% Effective

Pfizer and BioNTech announced Monday their coronavirus vaccine was more than 90% effective in preventing COVID-19 among those without evidence of prior infection, hailing the development as “a great ...

Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial

Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer ...

Pfizer Trial Updates Test Investor Views On Pipeline And Valuation

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Pfizer's Oncology Pipeline Gains Momentum with Promising Trial Data

The positive bladder cancer data follows closely on the heels of another regulatory achievement for the pharmaceutical giant. On February 24, the U.S. Food and Drug Administration (FDA) granted full ...
Fierce Biotech

Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...
Hosted on MSN

Pfizer weight-loss drug data raises questions about side effects, shares fall

Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug from its recent $10 billion Metsera purchase that raises questions about its tolerability for patients, and ...